ReviewCurrent osteoporosis reports2017
Bone Pain and Muscle Weakness in Cancer Patients.
Review in Current osteoporosis reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation.Scientific reports · 2024Pooled it
- Meta-analysis of the effect of sophora flavescens on tumor metastasis-induced bone neuropathic pain.Frontiers in pharmacology · 2024Pooled it
- Review
- Factors Associated with Discharge Destination in Patients with Bone Metastases.Medicina (Kaunas, Lithuania) · 2024Article
- Physical Activity, Alcohol, and Cigarette Use in Urological Cancer Patients over Time since Diagnosis.Healthcare (Basel, Switzerland) · 2023Article
- Management of cancer pain due to bone metastasis.Journal of bone and mineral metabolism · 2023Review
- Glycogen synthase kinase-3β inhibition decreases inflammation and relieves cancer induced bone pain via reducing Drp1-mediated mitochondrial damage.Journal of cellular and molecular medicine · 2022Article
- Mechanisms of bone pain: Progress in research from bench to bedside.Bone research · 2022Review
- Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies.JCO oncology practice · 2022Article
- Virtual Prehabilitation in Patients With Cancer Undergoing Surgery During the COVID-19 Pandemic: Protocol for a Prospective Feasibility Study.JMIR research protocols · 2022Article
- Protocol for the Pilot Study of Group Video Yogic Breathing App in Breast Cancer Survivors.International journal of AAYUSH and traditional medicine · 2022Article
- Interventional Therapies for Pain in Cancer Patients: a Narrative Review.Current pain and headache reports · 2021Review
- Interventional and Non-interventional Medical Rehabilitation Approaches to Axial Spine Pain in Vertebral Metastatic Disease.Frontiers in pain research (Lausanne, Switzerland) · 2021Review
- No Difference in the Phenotypic Expression of Frailty among Elderly Patients Recently Diagnosed with Cancer Vs Cancer Free Patients.The journal of nutrition, health & aging · 2020Article
- Optimization andFrontiers in pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewIn this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems. RECENT
findingsThere are several pharmacologic therapies that are currently in preclinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of noceciptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. CIBP and CIMW are significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.